Study Detail

CoVLP

A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older (CoVLP)

Status: Closed

Type: Interventional

Funder: Medicago

Sponsor: Medicago

CI: Dr Chrissie Jones

IRAS-Number: 296247

CPMS-ID: 47462

Approval Date: 21 December 2020

Summary:

A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older and Children and Adolescents 5-17 Years of Age

Study URL:

https://www.medicago.com/en/media-room/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/

Back to listing